The Fast Track designation and on-schedule enrollment de-risk the ANB033 program modestly, but the stock's next major catalyst is the Q4 2026 Cohort 1 data readout. Traders should monitor for any pre-data analyst upgrades or partnership speculation on rosnilimab, which could provide near-term upside before the binary data event.
Price Chart
Executive Summary
First Tracks Biotherapeutics reported Q2 2026 net loss of $33.4M ($0.95/share), narrower than the $42.4M loss in Q2 2025, driven by lower R&D costs post-spin-off. The key catalyst is the FDA Fast Track designation for lead asset ANB033 in celiac disease, with Cohort 1 Phase 1b data on track for Q4 2026 and cash runway reiterated into Q2 2028. The improved loss trajectory and regulatory milestone are positive, but the stock remains a binary event-driven play on clinical data readouts.
Key Financial Metrics
Key Facts
- FDA granted Fast Track designation for ANB033 in celiac disease.
- Cohort 1 Phase 1b ANB033 data reaffirmed for Q4 2026; Cohort 2 data expected Q1 2027.
- Q2 2026 net loss narrowed to $33.4M from $42.4M YoY, with EPS of -$0.95 vs -$1.47.
- Cash, cash equivalents and investments totaled $168.0M as of June 30, 2026; cash runway reiterated into Q2 2028.
- R&D expenses fell to $25.6M from $39.3M YoY due to lower rosnilimab costs, partially offset by ANB033 trial costs.
Financial Impact
Net loss improved by $9.0M YoY to $33.4M; cash burn rate of ~$28M/quarter supports runway into Q2 2028.
Risk Factors
- Phase 1b ANB033 data may fail to show efficacy, wiping out pipeline value.
- Cash runway into Q2 2028 assumes no unexpected trial delays or cost overruns.
- Rosnilimab strategic options may result in dilutive financing or unfavorable terms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-346908 |
| Document: trax-20260812.htm | 0001193125-26-346908 |
| Document: 0001193125-26-346908-index-headers.html | 0001193125-26-346908 |
| Document: 0001193125-26-346908-index.html | 0001193125-26-346908 |
| Document: 0001193125-26-346908.txt | 0001193125-26-346908 |
| 8-K Data (Synthetic) | 0001193125-26-346908 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers